U.S. Drug Company Sues Canada For Trying To Lower Cost Of $700K-A-Year Drug

The medication is approved to treat two rare blood diseases that affect about one in every one million people. A 12-month treatment costs about $700,000 in Canada, while in the U.S. it costs about $669,000. Continue reading

The post U.S. Drug Company Sues Canada For Trying To Lower Cost Of $700K-A-Year Drug appeared first on MintPress News.

Follow this story